The data presented here further demonstrate that inhibition of ALDH activity through either downregulation of ALDH1A1 expression, or treatment with the ALDH1A1 selective inhibitor, blocked both sphere formation capacity and tumorigenic potential of ovarian cancer cells, supporting the function of ALDH activity in CSC subpopulation maintenance in tumors. This evidence concerns the gene ALDH1A1 and ovarian cancer.